CMMB Q2 2022 Earnings — Chemomab Therapeutics Ltd. Revenue & Financial Results | Market Cap Arena

CMMBChemomab Therapeutics Ltd.

$12M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$6M

Operating Income

-$6M

Net Income

-$6M

EPS (Diluted)

$-2.13

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$56M

Total Liabilities

$5M

Stockholders' Equity

$52M

Cash & Equivalents

$10M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$6M	-$7,025	-88924.9%
Operating Income	-$6M	-$3M	-127.2%
Net Income	-$6M	-$3M	-123.5%